Haloperidol Pharmacokinetics after Oral and Intravenous administration in Elderly

Withdrawn

• Conditions: acute confusional state; delirium; 10012221

• Registration Number: NL-OMON43207
• Lead Sponsor: Kennemer Gasthuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

hip fracture surgery
65 years or over
DRAS score 5 or over
informed consent

Exclusion Criteria

haloperidol allergy
QTc prolongation
Parkinsons's disease
Lewy body dementia
use of anticoagulents
liver failure

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Nonlinear mixed effects model describing the population pharmacokinetics of<br /><br>haloperidol in the central and peripheral compartment after oral and<br /><br>intravenous injection.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Occurrence of adverse events and occurrence of postoperative delirium</p><br>